Stephens Downgrades Bio-Techne to Hold, Sets $73 Price Target
Stephens lowered its rating on Bio-Techne to hold, setting a $73 price target, a 2.96% upside from the current price.
Key Points
- Stephens downgraded Bio-Techne Corporation's stock to a hold rating, setting a price target of $73 on June 26, 2026.
- Stephens's $73 price target implies 2.96% upside from Bio-Techne Corporation's ($TECH) current $70.90 share price.
- Bio-Techne, with a market cap of about $11.06 billion, has a P/E ratio of 101.4 and a 52-week range between $43.20 and $72.16.
- Insider activity includes Steven Crouse selling 600 shares on June 2, 2026, while Amy Herr bought 6,636 shares on May 8, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 26, 2026, Stephens lowered its rating on Bio-Techne Corporation, listed on the NasdaqGS under the ticker TECH, to a hold. The firm set a price target of $73. Shares of Bio-Techne traded near $70.7 on Saturday.
Stephens & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Bio-Techne Corporation Stock Down 2.0%
Shares of NasdaqGS:TECH traded close to $70.7 on Saturday. Bio-Techne Corporation, with a market cap of approximately $11.06 billion, has a P/E ratio of 101.4 and a forward P/E of 34.7. The company's beta is 1.358, indicating a higher volatility compared to the market. Over the past year, the stock has ranged from a low of $43.20 to a high of $72.16. Its 50-day moving average is $53.02, while the 200-day moving average is $57.70. Bio-Techne has a strong current ratio of 4.49 and a quick ratio of 2.80, with a debt-to-equity ratio of 13.92.
$TECH price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Bio-Techne reported revenue of $1.21 billion, although it experienced a slight decline with a revenue growth of -1.5%. The company posted a net margin of 9.05% and a return on equity of 5.34%. Its earnings per share stood at $0.70. The next earnings report is expected on August 5, 2026.
Dividend
Bio-Techne offers an annual dividend rate of $0.32, yielding 0.45% with a payout ratio of 45.71%.
Insider Buying and Selling at Bio-Techne Corporation
Insider activity at Bio-Techne included several transactions. On June 2, 2026, Steven Crouse, President of Diagnostics and Spatial Biology, sold 600 shares. On the same day, he also bought 600 shares. Amy Herr purchased 6,636 shares on May 8, 2026, at an average price of $47.60, and sold the same amount later.
Analysts Set New Price Targets
On June 26, 2026, Stephens & Co. downgraded Bio-Techne to a hold with a price target of $73. Baird maintained its hold rating with the same target on the same day. Piper Sandler initiated coverage with a hold rating and a $65 target on June 11, 2026. The consensus among 12 analysts is a buy recommendation, with a mean price target of $65.75.
About Bio-Techne Corporation
Bio-Techne Corporation, headquartered in Minneapolis, Minnesota, develops and sells life science reagents, instruments, and services globally. The company operates through its Protein Sciences and Diagnostics and Spatial Biology segments. It provides essential tools for life science research, diagnostics, and bioprocessing, including cytokines, antibodies, and proteomic analytical tools. Bio-Techne was incorporated in 1976 and employs around 3,100 people.
Bottom Line
Stephens' downgrade of Bio-Techne reflects a cautious approach, setting a price target of $73. Bio-Techne's financials show a solid market position with a high P/E ratio, indicating investor confidence. The company's diverse product offerings in biotechnology make it a noteworthy player in the healthcare sector. Investors should note that analyst ratings and price targets are backward-looking assessments and may not reflect current market conditions.
Get Bio-Techne Corporation alerts
New 13F filings, insider trades, and analyst moves on $TECH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.